FAMAR Group Welcomes Dr. Riku Rautsola as New CEO Amid Leadership Transition

Leadership Change at FAMAR Group

In recent news from the pharmaceutical and cosmetic manufacturing sector, FAMAR Group has announced a critical leadership transition as Dr. Riku Rautsola steps in as the new CEO. This decision comes on the heels of Konstantinos Rengis's resignation after a noteworthy 16-year tenure at the company, during which he spent the last four years at the helm as CEO. Rengis made this choice for personal reasons, effective September 29, 2025.

Rengis's time at the company was marked by significant achievements. He was well-regarded for his customer-focused approach and extensive knowledge of the industry, which helped steer FAMAR through a series of ownership changes and operational improvements. His leadership style emphasized a solution-oriented mindset which not only enhanced customer service but also laid down a framework for future growth.

Rautsola, who has been intimately involved with FAMAR's strategic direction as a non-executive Board member and an advisor during last year’s acquisition by MidEuropa, is expected to bring a wealth of experience to his new role. With a rich background in the pharmaceutical, biotech, and CDMO (Contract Development and Manufacturing Organization) fields, Rautsola has previously held executive positions in several leading firms, where he successfully drove sustained profitable growth.

As the new CEO, Rautsola's agenda includes reinforcing FAMAR's commitment to serving its global clientele. He aims to enhance production capabilities, foster development partnerships, and invest in the company’s workforce. Importantly, Rautsola will also continue his contribution to corporate governance through his role on the Board of Directors, ensuring a smooth transition and continuity in leadership.

Rengis will not be departing from the company entirely; he will remain in a senior advisory role where he will focus on strategic customer relationships, thereby allowing for the knowledge transfer necessary during this transitional phase.

Matthew Strassberg, Partner and Head of Healthcare at MidEuropa, expressed gratitude for Rengis's years of dedicated service while emphasizing the potential that Rautsola brings to the company. The appointment reflects not just a change in leadership but a strategic shift towards innovation and future expansion.

FAMAR Group positions itself as a prominent entity in Europe’s pharmaceutical and cosmetics manufacturing landscape. With a legacy spanning over 75 years, the company is known for its high-quality production capabilities, which include a diverse range of dosage forms such as sterile liquids, solids, and semi-solids. FAMAR’s operations span multiple countries, including Spain, Italy, and Greece, employing more than 1,850 individuals across six manufacturing sites and two research and development centers. With over 1,700 different products under its belt, FAMAR services more than 80 global markets, underscoring its role as a significant player in the global pharmaceutical arena.

As Dr. Rautsola embarks on this new journey, the industry watches closely to see how his leadership will evolve the company and respond to the ever-changing demands of the pharmaceutical market.